Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment.

ACUTE LIVER FAILURE ALCOHOLIC LIVER DISEASE CHRONIC LIVER DISEASE HEPATOCELLULAR CARCINOMA NONALCOHOLIC STEATOHEPATITIS

Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
22 Aug 2024
Historique:
received: 15 04 2024
accepted: 24 07 2024
medline: 23 8 2024
pubmed: 23 8 2024
entrez: 22 8 2024
Statut: aheadofprint

Résumé

Advancements in omics technologies and artificial intelligence (AI) methodologies are fuelling our progress towards personalised diagnosis, prognosis and treatment strategies in hepatology. This review provides a comprehensive overview of the current landscape of AI methods used for analysis of omics data in liver diseases. We present an overview of the prevalence of different omics levels across various liver diseases, as well as categorise the AI methodology used across the studies. Specifically, we highlight the predominance of transcriptomic and genomic profiling and the relatively sparse exploration of other levels such as the proteome and methylome, which represent untapped potential for novel insights. Publicly available database initiatives such as The Cancer Genome Atlas and The International Cancer Genome Consortium have paved the way for advancements in the diagnosis and treatment of hepatocellular carcinoma. However, the same availability of large omics datasets remains limited for other liver diseases. Furthermore, the application of sophisticated AI methods to handle the complexities of multiomics datasets requires substantial data to train and validate the models and faces challenges in achieving bias-free results with clinical utility. Strategies to address the paucity of data and capitalise on opportunities are discussed. Given the substantial global burden of chronic liver diseases, it is imperative that multicentre collaborations be established to generate large-scale omics data for early disease recognition and intervention. Exploring advanced AI methods is also necessary to maximise the potential of these datasets and improve early detection and personalised treatment strategies.

Identifiants

pubmed: 39174307
pii: gutjnl-2023-331740
doi: 10.1136/gutjnl-2023-331740
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Soumita Ghosh (S)

Transplant AI Initiative, Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada.
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Xun Zhao (X)

Transplant AI Initiative, Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada.

Mouaid Alim (M)

Transplant AI Initiative, Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada.
Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.

Michael Brudno (M)

Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Vector Institute of Artificial Intelligence, Toronto, Ontario, Canada.

Mamatha Bhat (M)

Transplant AI Initiative, Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada Mamatha.Bhat@uhn.ca.
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Division of Gastroenterology, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.

Classifications MeSH